Overall, the significant differences in tumor size and particularly in recurrence rate suggest that this 3-gene expression signature (DEPTOR, APOE, APOC1, with the specified OR logic for APOE/APOC1) holds potential for distinguishing PTC patients with differing prognostic outcomes, broadly consistent with the prognostic implications derived from our primary bioinformatics analysis of OSPTCC subtypes. Here, APOC1 is linked to neoplasm.